Supportive care in myeloma—when treating the clone alone is not enough

2.

Delforge

M

,

Patel

K

,

Eliason

L

, et al.

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient- reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

.

Lancet Haematol

.

2024

;

11

(

3

):

e216

-

e227

.

3.

Terpos

E

,

Zamagni

E

,

Lentzsch

S

, et al;

Bone Working Group of the International Myeloma Working Group

.

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

.

Lancet Oncol

.

2021

;

22

(

3

):

e119

-

e130

.

4.

Terpos

E

,

Ntanasis-Stathopoulos

I

,

Gavriatopoulou

M

,

Dimopoulos

MA

.

Pathogenesis of bone disease in multiple myeloma: from bench to bedside

.

Blood Cancer J

.

2018

;

8

(

1

):

7

.

5.

Nakaue

E

,

Teramachi

J

,

Tenshin

H

, et al.

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors

.

Int J Hematol

.

2023

;

118

(

1

):

88

-

98

.

6.

Giuliani

N

,

Morandi

F

,

Tagliaferri

S

, et al.

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

.

Blood

.

2007

;

110

(

1

):

334

-

338

.

7.

Mhaskar

R

,

Kumar

A

,

Miladinovic

B

,

Djulbegovic

B.

Bisphosphonates in multiple myeloma: an updated network meta-analysis

.

Cochrane Database Syst Rev

.

2017

;

12

(

12

):

CD003188

.

8.

Noopur

R

,

Evangelos

T

,

Wolfgang

W

, et al.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

.

Lancet Oncol

.

2018

;

19

(

3

):

370

-

381

.

9.

Himelstein

AL

,

Foster

JC

,

Khatcheressian

JL

, et al.

Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial

.

JAMA

.

2017

;

317

(

1

):

48

-

58

.

10.

Morgan

GJ

,

Davies

FE

,

Gregory

WM

, et al;

National Cancer Research Institute Haematological Oncology Clinical Studies Group

.

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX trial

.

Blood

.

2012

;

119

(

23

):

5374

-

5383

.

11.

Tsourdi

E

,

Langdahl

B

,

Cohen-Solal

M

, et al.

Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS

.

Bone

.

2017

;

105

:

11

-

17

.

12.

Regelink

JC

,

Raijmakers

PG

,

Bravenboer

N

, et al.

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma

.

EJNMMI Res

.

2016

;

6

(

1

):

46

.

13.

Regelink

JC

,

Zwezerijnen

GJC

,

Groen

RJW

,

Raijmakers

PG

,

Zweegman

S.

In vivo 18 F-fluoride-PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients

.

Br J Haematol

.

2023

;

200

(

6

):

755

-

758

.

14.

Frenzel

L

,

Decaux

O

,

Macro

M

, et al.

Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group

.

Thromb Res

.

2024

;

233

:

153

-

164

.

15.

Palumbo

A

,

Rajkumar

SV

,

Dimopoulos

MA

, et al;

International Myeloma Working Group

.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

.

Leukemia

.

2008

;

22

(

2

):

414

-

423

.

16.

Larocca

A

,

Cavallo

F

,

Bringhen

S

, et al.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

.

Blood

.

2012

;

119

(

4

):

933

-

939

; quiz 1093.

17.

Geoffrey

M

,

Kimberly

Y

,

Courtney

S

, et al.

Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma

.

Eur J Haematol

.

2022

;

109

(

5

):

559

-

565

.

18.

Chalayer

E

,

Talbot

A

,

Frenzel

L

, et al.

Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM/DFCI 2009 cohort

.

J Thromb Haemost

.

2022

;

20

(

8

):

1859

-

1867

.

19.

Charalampous

C

,

Shah

D

,

Kumar

S

,

Chakraborty

R.

Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines [published online 17 April 2024]

.

Ann Hematol

.

20.

Chakraborty

R

,

Bin Riaz

I

,

Malik

SU

, et al.

Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis

.

Cancer

.

2020

;

126

(

8

):

1640

-

1650

.

21.

Sanfilippo

KM

,

Luo

S

,

Wang

TF

, et al.

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

.

Am J Hematol

.

2019

;

94

(

11

):

1176

-

1184

.

22.

Li

A

,

Wu

Q

,

Luo

S

, et al.

Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma

.

J Natl Compr Canc Netw

.

2019

;

17

(

7

):

840

-

847

.

23.

Chakraborty

R

,

Rybicki

L

,

Wei

W

, et al.

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

.

Blood

.

2022

;

140

(

23

):

2443

-

2450

.

24.

Rajkumar

SV

,

Jacobus

S

,

Callander

NS

, et al;

Eastern Cooperative Oncology Group

.

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

.

Lancet Oncol

.

2010

;

11

(

1

):

29

-

37

.

25.

Cornell

RF

,

Goldhaber

SZ

,

Engelhardt

BG

, et al.

Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents

.

Br J Haematol

.

2020

;

190

(

4

):

555

-

561

.

26.

Pegourie

B

,

Karlin

L

,

Benboubker

L

, et al.

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: myelaxat, a phase 2 pilot study

.

Am J Hematol

.

2019

;

94

(

6

):

635

-

640

.

27.

Piedra

K

,

Peterson

T

,

Tan

C

, et al.

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

.

Br J Haematol

.

2022

;

196

(

1

):

105

-

109

.

28.

Verkleij

CPM

,

Broekmans

MEC

,

van Duin

M

, et al.

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

.

Blood Adv

.

2021

;

5

(

8

):

2196

-

2215

.

29.

Rodriguez-Otero

P

,

Usmani

S

,

Cohen

AD

, et al;

International Myeloma Working Group

.

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

.

Lancet Oncol

.

2024

;

25

(

5

):

e205

-

e216

.

30.

Ajai

C

,

Monique

CM

,

Jesus

GB

, et al.

Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma

.

New Engl J Med

.

2022

;

387

(

24

):

2232

-

2244

.

31.

Carlo-Stella

C

,

Mazza

R

,

Manier

S

, et al.

RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

.

Blood

.

2022

;

140

(

suppl 1

):

397

-

399

.

32.

Sham

M

,

Sean

MD

,

Jonathan

L

, et al.

GPRC5D-targeted CAR T cells for myeloma

.

N Engl J Med

.

2022

;

387

(

13

):

1196

-

1206

.

33.

Xia

J

,

Li

H

,

Yan

Z

, et al.

Anti–G protein–coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase II trial

.

J Clin Oncol

.

2023

;

41

(

14

):

2583

-

2593

.

34.

Zhang

M

,

Wei

G

,

Zhou

L

, et al.

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

.

Lancet Haematol

.

2023

;

10

(

2

):

e107

-

e116

.

35.

Chari

A

,

Touzeau

C

,

Schinke

C

, et al.

Talquetamab, a G protein-coupled receptor family C group 5 member D × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results from MonumenTAL-1

.

Blood

.

2022

;

140

(

suppl 1

):

384

-

387

.

36.

Laheij

AMGA

,

van de Donk

NWCJ

.

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab

.

Support Care Cancer

.

2023

;

32

(

1

):

20

.

37.

Schuurhuizen

CSEW

,

Marino

P

,

Braamse

AMJ

, et al.

Impact of patient- and clinician-reported cumulative toxicity on quality of life in patients with metastatic castration-naïve prostate cancer

.

J Natl Compr Canc Netw

.

2018

;

16

(

12

):

1481

-

1488

.

38.

Engelhardt

M

,

Ihorst

G

,

Singh

M

, et al.

Real-world evaluation of health- related quality of life in patients with multiple myeloma from Germany

.

Clin Lymphoma Myeloma Leuk

.

2021

;

21

(

2

):

e160

-

e175

.

39.

Chari

A

,

Oriol

A

,

Krishnan

A

, et al.

Efficacy and safety of less frequent/lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma: results from the phase 1/2 MonumenTAL-1 study

.

Blood

.

2023

;

142

(

suppl 1

):

1010

.

40.

Blimark

C

,

Holmberg

E

,

Mellqvist

UH

, et al.

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

.

Haematologica

.

2015

;

100

(

1

):

107

-

113

.

41.

Ludwig

H

,

Boccadoro

M

,

Moreau

P

, et al.

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

.

Leukemia

.

2021

;

35

(

1

):

31

-

44

.

42.

Raje

NS

,

Anaissie

E

,

Kumar

SK

, et al.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

.

Lancet Haematol

.

2022

;

9

(

2

):

e143

-

e161

.

43.

Chapel

HM

,

Lee

M

,

Hargreaves

R

,

Pamphilon

DH

,

Prentice

AG

;

UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

.

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma

.

Lancet

.

1994

;

343

(

8905

):

1059

-

1063

.

44.

Raanani

P

,

Gafter-Gvili

A

,

Paul

M

,

Ben-Bassat

I

,

Leibovici

L

,

Shpilberg

O.

Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis

.

Leuk Lymphoma

.

2009

;

50

(

5

):

764

-

772

.

45.

Frerichs

KA

,

Bosman

PWC

,

van Velzen

JF

, et al.

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

.

Haematologica

.

2020

;

105

(

6

):

e302

-

e306

.

46.

Rodriguez

C

,

Perrot

A

,

Richardson

PG

, et al.

The impact of isatuximab regimens on hypogammaglobulinemia occurrence, recovery, and associated infections in patients with relapsed/refractory multiple myeloma

.

Blood

.

2023

;

142

(

suppl 1

):

1980

.

47.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

.

Nat Med

.

2023

;

29

(

9

):

2295

-

2306

.

48.

O'Connor

BP

,

Raman

VS

,

Erickson

LD

, et al.

BCMA is essential for the survival of long-lived bone marrow plasma cells

.

J Exp Med

.

2004

;

199

(

1

):

91

-

98

.

49.

Frerichs

KA

,

Broekmans

MEC

,

Marin Soto

JA

, et al.

Preclinical activity of JNJ-7957, a novel BCMA × CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab

.

Clin Cancer Res

.

2020

;

26

(

9

):

2203

-

2215

.

50.

Frerichs

KA

,

Verkleij

CPM

,

Mateos

MV

, et al.

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

.

Blood Adv

.

2024

;

8

(

1

):

194

-

206

.

51.

Lesokhin

A

,

Nath

K

,

Shekarkhand

T

, et al.

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma [published online 7 February 2024]

.

Res Sq.

52.

D'Souza

A

,

Shah

N

,

Rodriguez

C

, et al.

A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2022

;

40

(

31

):

3576

-

3586

.

53.

Bar

N

,

Mateos

MV

,

Ribas

P

, et al.

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2 + 1 B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study

.

Blood

.

2023

;

142

(

suppl 1

):

2011

.

54.

Nooka

AK

,

Rodriguez

C

,

Mateos

MV

, et al.

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

.

Cancer

.

2024

;

130

(

6

):

886

-

900

.

55.

Trudel

S

,

Cohen

AD

,

Krishnan

AY

, et al.

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study

.

Blood

.

2021

;

138

(

suppl 1

):

157

.

56.

Jourdes

A

,

Cellerin

E

,

Touzeau

C

, et al;

G2I and the IFM networks

.

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

.

Clin Microbiol Infect

.

2024

;

30

(

6

):

764

-

771

.

57.

Contejean

A

,

Janssen

C

,

Orsini-Piocelle

F

,

Zecchini

C

,

Charlier

C

,

Chouchana

L.

Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study

.

Am J Hematol

.

2023

;

98

(

12

):

E349

-

E353

.

58.

Rubinstein

SM

,

Derman

BA

.

Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies

.

Eur J Cancer

.

2023

;

189

:112926.

59.

Kampouri

E

,

Little

JS

,

Rejeski

K

,

Manuel

O

,

Hammond

SP

,

Hill

JA

.

Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies

.

Transpl Infect Dis

.

2023

;

25

(

suppl 1

):

e14157

.

60.

Jesús

SM

,

Binod

D

,

Kwee

Y

, et al.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

.

N Engl J Med

.

2023

;

389

(

4

):

335

-

347

.

61.

Rodriguez-Otero

P

,

Ailawadhi

S

,

Arnulf

B

, et al.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2023

;

388

(

11

):

1002

-

1014

.

62.

Rejeski

K

,

Subklewe

M

,

Aljurf

M

, et al.

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

.

Blood

.

2023

;

142

(

10

):

865

-

877

.

63.

Rejeski

K

,

Wang

Y

,

Hansen

DK

, et al.

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

.

Blood Adv

.

2024

;

8

(

8

):

1857

-

1868

.

64.

Rejeski

K

,

Perez

A

,

Sesques

P

, et al.

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

.

Blood

.

2021

;

138

(

24

):

2499

-

2513

.

65.

Lancman

G

,

Parsa

K

,

Kotlarz

K

, et al.

IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies

.

Blood Cancer Discov

.

2023

;

4

(

6

):

440

-

451

.

66.

Raje

N

,

Anderson

K

,

Einsele

H

, et al.

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

.

Blood Cancer J

.

2023

;

13

(

1

):

116

.

67.

Ludwig

H

,

Terpos

E

,

van de Donk

N

, et al.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

.

Lancet Oncol

.

2023

;

24

(

6

):

e255

-

e269

.

68.

Lin

Y

,

Qiu

L

,

Usmani

S

, et al.

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

.

Lancet Oncol

.

2024

;

25

(

8

):

e374

-

e387

.

69.

Drayson

MT

,

Bowcock

S

,

Planche

T

, et al;

TEAMM Trial Management Group and Trial Investigators

.

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo- controlled, randomised, phase 3 trial

.

Lancet Oncol

.

2019

;

20

(

12

):

1760

-

1772

.

70.

Riedhammer

C

,

Bassermann

F

,

Besemer

B

, et al.

Real-world analysis of teclistamab in 123 RRMM patients from Germany

.

Leukemia

.

2024

;

38

(

2

):

365

-

371

.

71.

Mohan

M

,

Monge

J

,

Shah

N

, et al.

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

.

Blood Cancer J

.

2024

;

14

(

1

):

35

.

72.

Dima

D

,

Davis

JA

,

Ahmed

N

, et al.

Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience

.

Transplant Cell Ther

.

2024

;

30

(

3

):

308.e1

-

308308.e13

.

73.

Munshi

NC

,

Anderson

LD

Jr,

Shah

N

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

-

716

.

74.

Usmani

S

,

Patel

K

,

Hari

P

, et al.

KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation

.

Blood

.

2022

;

140

(

suppl 1

):

875

-

877

.

75.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet

.

2021

;

398

(

10297

):

314

-

324

.

76.

Kambhampati

S

,

Sheng

Y

,

Huang

CY

, et al.

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy

.

Blood Adv

.

2022

;

6

(

7

):

2045

-

2054

.

77.

Logue

JM

,

Peres

LC

,

Hashmi

H

, et al.

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

.

Blood Adv

.

2022

;

6

(

24

):

6109

-

6119

.

78.

Wang

Y

,

Li

C

,

Xia

J

, et al.

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

.

Blood Adv

.

2021

;

5

(

23

):

5290

-

5299

.

79.

Josyula

S

,

Pont

MJ

,

Dasgupta

S

, et al.

Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma

.

Transplant Cell Ther

.

2022

;

28

(

6

):

304.e1

-

304304.e9

.

80.

Mikkilineni

L

,

Yates

B

,

Steinberg

SM

, et al.

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days

.

Blood Adv

.

2021

;

5

(

23

):

5312

-

5322

.

81.

Little

JS

,

Tandon

M

,

Hong

JS

, et al.

Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy

.

Blood Adv

.

2023

;

7

(

18

):

5485

-

5495

.

82.

Terpos

E

,

Viniou

N

,

de la Fuente

J

, et al.

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

.

Eur J Haematol

.

2003

;

70

(

1

):

34

-

42

.

83.

Rosen

LS

,

Gordon

D

,

Kaminski

M

, et al.

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

.

Cancer

.

2003

;

98

(

8

):

1735

-

1744

.

84.

Gimsing

P

,

Carlson

K

,

Turesson

I

, et al.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma StudyGroup): a double-blind, randomised controlled trial

.

Lancet Oncol

.

2010

;

11

(

10

):

973

-

982

.

85.

Morgan

GJ

,

Davies

FE

,

Gregory

WM

,

Cocks

K

, et al.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

.

Lancet

.

2010

;

376

(

9757

):

1989

-

1999

.

86.

Raje

N

,

Terpos

E

,

Willenbacher

W

, et al.

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

.

Lancet Oncol

.

2018

;

19

(

3

):

370

-

381

.